Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Arvinas Holding Company ( (ARVN) ) just unveiled an update.
At the annual meeting held on June 25, 2025, Arvinas Holding Company stockholders elected new Class I directors to the board, approved a non-binding advisory proposal on executive compensation, and ratified Deloitte & Touche LLP as the independent accounting firm for the fiscal year ending December 31, 2025. These decisions reflect the company’s ongoing governance and financial oversight strategies, potentially impacting its operational stability and stakeholder confidence.
The most recent analyst rating on (ARVN) stock is a Buy with a $16.00 price target. To see the full list of analyst forecasts on Arvinas Holding Company stock, see the ARVN Stock Forecast page.
Spark’s Take on ARVN Stock
According to Spark, TipRanks’ AI Analyst, ARVN is a Neutral.
The overall stock score reflects a blend of strong revenue growth and positive strategic initiatives, offset by profitability challenges and mixed technical indicators. The company’s strong cash position and promising clinical pipeline contribute positively, while valuation concerns and restructuring efforts present risks.
To see Spark’s full report on ARVN stock, click here.
More about Arvinas Holding Company
Average Trading Volume: 2,643,533
Technical Sentiment Signal: Sell
Current Market Cap: $550.4M
See more insights into ARVN stock on TipRanks’ Stock Analysis page.